Get the Stockscreener App
8.22
0.48%
-0.04
After Hours:
8.42
0.20
+2.43%
Puma Biotechnology Inc stock is traded at $8.22, with a volume of 444.01K.
It is down -0.48% in the last 24 hours and up +16.93% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$8.26
Open:
$8.26
24h Volume:
444.01K
Relative Volume:
1.55
Market Cap:
$418.39M
Revenue:
$227.18M
Net Income/Loss:
$24.38M
P/E Ratio:
17.22
EPS:
0.4774
Net Cash Flow:
$53.60M
1W Performance:
+0.37%
1M Performance:
+16.93%
6M Performance:
+40.27%
1Y Performance:
+129.61%
1-Day Range:
$8.08
$8.44
1-Week Range:
$7.86
$8.44
52-Week Range:
$3.03
$8.44
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
8.22 | 412.79M | 227.18M | 24.38M | 53.60M | 0.4774 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Puma Biotechnology, Inc.(NasdaqGS: PBYI) added to Russell 2500 Growth Benchmark - marketscreener.com
Puma Biotechnology, Inc.(NasdaqGS: PBYI) added to Russell 2000 Growth Benchmark - marketscreener.com
Puma Biotechnology, Inc.(NasdaqGS: PBYI) added to Russell 3000E Growth Benchmark - marketscreener.com
Puma Biotechnology, Inc.(NasdaqGS:PBYI) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Enterprise value to revenue forward of Puma Biotechnology Inc – BOATS:PBYI - TradingView
Enterprise value to EBITDA forward of Puma Biotechnology Inc – NASDAQ:PBYI - TradingView
PBYI Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Puma Biotechnology Inc – NASDAQ:PBYI - TradingView
Price to sales forward of Puma Biotechnology Inc – BOATS:PBYI - TradingView
Enterprise value to EBIT forward of Puma Biotechnology Inc – BOATS:PBYI - TradingView
Enterprise value to EBITDA forward of Puma Biotechnology Inc – BOATS:PBYI - TradingView
Puma Biotechnology, Inc. Actuals & Estimates (NASDAQ:PBYI) - TradingView
Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates - Kavout | AI
Puma Pharmaceuticals Puma Biotechnology Puma Biotechnology Puma 2019 Revenue Breast Cancer Treatment - consumerthai.org
Puma Biotechnology Inc (PBYI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Puma Biotechnology Inc (PBYI) Institutional Confidence - TradingKey
PBYI SEC FilingsPuma Biotechnology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Puma Biotechnology Inc (PBYI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Puma Biotechnology Inc (PBYI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Puma Biotechnology Inc (PBYI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Puma Biotechnology Inc (PBYI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Puma Biotechnology Inc (PBYI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Puma Biotechnology Inc (PBYI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Puma Biotechnology StockShareholders back board but reject warrant extension - AD HOC NEWS
Puma Biotechnology shareholders elect directors and vote on key proposals - Investing.com UK
Puma Biotechnology shareholders elect directors and vote on key proposals By Investing.com - Investing.com South Africa
Puma Biotechnology Shareholders Back Governance, Reject Warrant Extension - TipRanks
Puma Biotechnology (PBYI) investors reelect full board but vote down one proposal - Stock Titan
Puma Biotechnology director Jay Moyes sells $158k in stock By Investing.com - Investing.com India
Puma Biotechnology director Jay Moyes sells $158k in stock - Investing.com UK
Puma Biotechnology director Adrian Senderowicz sells $194,310 in stock - Investing.com UK
Puma Biotechnology director Adrian Senderowicz sells $194,310 in stock By Investing.com - Investing.com India
Puma biotechnology director Brian Stuglik sells $58,311 in stock By Investing.com - Investing.com India
Puma biotechnology director Troy Wilson sells $77,748 of stock By Investing.com - Investing.com Nigeria
PUMA Biotechnology (PBYI) director trades shares, receives 27,000 RSUs grant - Stock Titan
PUMA Biotechnology (PBYI) director gets 27,000-share award, sells 22,000 shares - Stock Titan
Puma Biotechnology (PBYI) Slides 2.5% as Support Test Looms Near $6.79MFI Divergence - newsline.com
Puma Biotechnology stock rises 19% in 3 months: Here's why - MSN
Cash per share of Puma Biotechnology, Inc. – TRADEGATE:0PB - TradingView
[144] PUMA BIOTECHNOLOGY, INC. SEC Filing - Stock Titan
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why - TradingView
Puma Raised to Buy From Neutral by Citi - Moomoo
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 3, 2026 - BioSpace
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule - TradingView
PBYIPuma Biotechnology Inc Stock Price and Quote - Finviz
Puma Biotechnology PBYI Edges Higher Amidst Key Support and Resistance LevelsThe Legal Advocate - The Legal Advocate
Puma Biotechnology (PBYI) Edges Higher Amidst Key Support and Resistance LevelsPercent Below MA - newsline.com
PBYI Stock Price, Quote & Chart | PUMA BIOTECHNOLOGY INC (NASDAQ:PBYI) - ChartMill
PBYI Stock Inches Higher: The Quiet Puma Biotechnology Signal Investors Are Watching - Bez Kabli
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Puma Biotechnology Inc Stock (PBYI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Stuglik Brian M | Director |
Jun 12 '26 |
Sale |
7.20 |
8,100 |
58,311 |
113,858 |
| Senderowicz Adrian | Director |
Jun 12 '26 |
Sale |
7.20 |
27,000 |
194,311 |
27,000 |
| MOYES JAY M | Director |
Jun 12 '26 |
Sale |
7.22 |
22,000 |
158,796 |
58,322 |
| Dorval Allison | Director |
Jun 12 '26 |
Sale |
7.20 |
11,610 |
83,579 |
90,780 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):